Zhang Tian, Liu Yang, Yan Jun-Kai, Cai Wei
School of Medicine, Xinhua Hospital, Shanghai Jiao Tong University, Shanghai, China.
Shanghai Key Laboratory of Pediatric Gastroenterology and Nutrition, Shanghai Institute for Pediatric Research, Shanghai, China.
FASEB J. 2020 Mar;34(3):4670-4683. doi: 10.1096/fj.201902513R. Epub 2020 Feb 6.
Intestinal barrier dysfunction is a major complication of total parenteral nutrition (TPN). Our preliminary study revealed that intestinal P-glycoprotein (P-gp) was significantly downregulated under TPN treatment followed by disruption of barrier function, and thus the significance of early downregulation of P-gp needs to be addressed. Herein, we report a pivotal role of P-gp in the development of intestinal barrier dysfunction under TPN. Functional suppression of P-gp may facilitate bacterial attachment to intestinal epithelial cells (IECs) and thereby induce degradation of tight junctions to trigger barrier dysfunction. By using a rat model of TPN, we found early downregulation of P-gp function in ileum after 3-day TPN, followed by disruption of barrier function after 7-day TPN. By using Escherichia coli (E. coli) k88 and DH5α as type strains, we found significantly increased bacterial attachment to IECs in TPN group compared to sham. By using Caco-2 cells as an IEC model in vitro, we found that functional suppression of P-gp remarkably facilitated bacterial attachment to Caco-2 cells, leading to subsequent disruption of intestinal barrier function. Of note, Occludin was significantly downregulated by bacterial attachment when P-gp was functionally suppressed. Mechanistically, changes on Occludin were attributed to enhanced protein degradation instead of suppressed protein translation. Despite the half-life of Occludin protein being unchanged by DH5α treatment alone, it was decreased by about 40% when P-gp was simultaneously suppressed. Taken together, our findings revealed that early downregulation of intestinal P-gp under TPN may be a potential therapeutic target to prevent the development of barrier dysfunction.
肠屏障功能障碍是全肠外营养(TPN)的主要并发症。我们的初步研究表明,在TPN治疗下肠道P-糖蛋白(P-gp)显著下调,随后屏障功能遭到破坏,因此P-gp早期下调的意义需要得到阐明。在此,我们报告P-gp在TPN所致肠屏障功能障碍发展过程中的关键作用。P-gp的功能抑制可能促进细菌黏附于肠上皮细胞(IECs),从而诱导紧密连接降解,引发屏障功能障碍。通过使用TPN大鼠模型,我们发现TPN 3天后回肠中P-gp功能早期下调,7天后屏障功能遭到破坏。以大肠杆菌(E. coli)k88和DH5α作为典型菌株,我们发现与假手术组相比,TPN组中细菌对IECs的黏附显著增加。通过使用Caco-2细胞作为体外IEC模型,我们发现P-gp的功能抑制显著促进细菌对Caco-2细胞的黏附,导致随后的肠屏障功能破坏。值得注意的是,当P-gp功能受到抑制时,细菌黏附会使闭合蛋白显著下调。从机制上讲,闭合蛋白的变化归因于蛋白质降解增强而非蛋白质翻译受到抑制。尽管单独用DH5α处理时闭合蛋白的半衰期未变,但当P-gp同时受到抑制时,其半衰期降低了约40%。综上所述,我们的研究结果表明,TPN下肠道P-gp的早期下调可能是预防屏障功能障碍发展的潜在治疗靶点。